Successful treatment of locally advanced lung cancer using late concurrent chemoradiation therapy administered after immune checkpoint inhibitor plus platinum chemotherapy
Abstract Concurrent chemoradiation therapy (CRT) is the standard of care for patients with unresectable stage II/III lung cancer. However, systemic chemotherapy is required for patients who are ineligible for radical radiation therapy. There is little evidence to date for the safety and efficacy of...
Enregistré dans:
Auteurs principaux: | Taichi Matsubara, Shinkichi Takamori, Takatoshi Fujishita, Ryo Toyozawa, Kensaku Ito, Masafumi Yamaguchi, Takashi Seto, Tatsuro Okamoto |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Wiley
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/34e9b456402f4b74b9a51df3acabdd4c |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Adaptive Radiation Therapy in the Treatment of Lung Cancer: An Overview of the Current State of the Field
par: Huzaifa Piperdi, et autres
Publié: (2021) -
Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer
par: Nathaniel Wiest, et autres
Publié: (2021) -
Immunotherapy in the First-Line Treatment of NSCLC: Current Status and Future Directions in China
par: Anwen Xiong, et autres
Publié: (2021) -
Rapidly Destructive Coxarthrosis as a Potential Side Effect of Crizotinib in a Patient with ROS1-Positive Lung Adenocarcinoma
par: Takamori S, et autres
Publié: (2020) -
Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer
par: Barrows SM, et autres
Publié: (2019)